Viaskin™ Peanut’s Long-Term Phase III Updates and What the FDA Has to Say About Them | BioSpace

Originally published: Aug 14, 2020

With only one FDA-approved therapy and standard-of-care treatment including avoidance and carrying an EpiPen in case of accidental exposure, the unmet need for peanut allergies is huge. Not to mention that peanut allergy is the most common food allergy in children, affecting 2.5% of U.S. children — nearly 1.8 million children and adults.

DBV Technologies aims to fill the peanut allergy treatment gap, especially for highly allergic children, with their low dose epicutaneous immunotherapy (EPIT) patch Viaskin™ Peanut.

“There’s an emotional aspect to the product — you’re putting this patch on your young child’s back every day instead of forcing them to eat something they might be dreading,” Pharis Mohideen, MD, Chief Medical Officer at DBV Technologies, told BioSpace. “It’s a nice feeling that you’re doing something you feel is going to make a difference and help them.”

Mohideen also has a unique perspective, wearing both clinical and personal hats. “I’m the father of two children who have food allergies, so I’ve been living this for about 15 or 16 years,” he added. “I think I have a slightly different perspective than the average chief medical officer.”